Press Release
New DCAT Leadership Takes Office November 1
Robbinsville, NJ, USA November 1, 2017 -- DCAT is pleased to announce that the slate of candidates recommended by DCAT’s Leadership Development Committee for the 2017-2018 Board of Directors and Advisory Council was approved by member company official delegates. Elected members will take office on November 1, 2017.
Leading the Board of Directors as president will be Joe Sutton, Global Director, Sourcing at Eli Lilly and Company. Joining him in the important work of developing and guiding the organization's plans and policies are:
First Vice President:
Paolo Magri, Senior Vice President, Business Development, Advitech SA
Second Vice President: Dr. Stephan Kutzer, CEO, Alcami Corporation
Third Vice President:
Sean Diver, Director, Business Development, Early Intermediates, Lonza AG.
The Board of Directors also welcomes several newly-elected directors, each serving a one-year term:
- Anita Anderson, Senior Director, Business Development, Gyma Laboratories of America, Inc.
- Elizabeth Iorns, Ph.D., CEO, Science Exchange
- Sally Macaluso, Vice President, J&J Business Services Procurement, Johnson & Johnson
- Kerri McCullough Wood, Senior Vice President, Head of Commercial, TAPI
- Oliver Technow, President, BioVectra, Inc.
The DCAT Advisory Council consists of 18 member representatives serving three-year terms from various segments of the industry, with six members rotating on/off each year. The newly elected members below are charged with providing insights, guidance and expertise to the Board of Directors, as well as to the committees and task forces that they serve on.
- Kelsey Achenbach, Head of Marketing, Pharmaceuticals, Roquette
- Alessandra Barazza, Associate Director, Bristol-Myers Squibb
- Elodie Cramer, Associate Director, Global Procurement, Biogen
- Pauel Fokin, Regional Commercial Director, The Dow Chemical Company
- Donna Gruol, Director, Business Development, Xellia Pharmaceuticals LLC
- Vijay Ramanavarapu, President, Granules USA Inc.
In addition, the following individuals were appointed to complete unexpired terms on the Advisory Council:
- Syed T. Husain, Chief Commercial Officer, Alcami Corporation
- Robert Geiger, Vice President, Generic APIs, AmbioPharm, Inc.
The DCAT Program Management Council consists of the chairs of its standing committees which are charge with identifying the needs of the members, and managing initiatives consistent with the organization’s goals and objectives. The committee chairs are as follows:
- Education Committee: Gavin Murdoch, Senior Director, Strategic Partnerships, Patheon
- Marketing Committee: Erin O’Brien, Senior Director, Product Management, Vial Containment & Delivery, West Pharmaceutical Services, Inc.
- Science & Scholarship Committee: Scott R. Price, Vice President, Sales, Ren-Pharm International
- Supply Management Committee: Rebecca A. Bishop, Strategic Sourcing Manager, Eli Lilly and Company (new appointment)
- Women in Pharma Committee: Lori Hoffman, Senior Director, Alliance Management, Frontida BioPharm, Inc.
Leadership Completing Terms of Service
The DCAT organization would also like to thank the following dedicated leaders who have given generously of their time and provided invaluable insights to help the organization better serve its member companies.
Board of Directors (completed terms)
- Milton Boyer, President
CEO, SCA Pharmaceuticals
(Mr. Boyer will continue on the Board as Immediate Past President)
- George Svokos, Past President
COO, AMRI
Detlef Behrens, Ph.D., Director
Head, CMO, Biocon Ltd.
- Michael Humora, Ph.D., Director
Director, J-STAR Research, Inc.
- Scott Zook, Director
Vice President, CMC Development, Neurocrine Biosciences
Advisory Council (completed terms)
- Charles Davies, Vice President, Global Procurement, Global Lead – Third Party Operations Procurement, Teva Pharmaceuticals USA, Inc.
- Sean Diver, Director, Business Development, Early Intermediates, Lonza, Inc.
- Bill Grubb, Vice President, Commercial, Noramco, Inc.
- Brian Shaughnessy, Senior Vice President, Sales & Marketing, Discovery & Chemical Development Services, GVK Biosciences Private Limited
- Marianne Spaene, Executive Vice President, Global Head Business Development, Marketing & Sales, Siegfried AG
- Andreas Weiler, Business Unite Head, Emerging Technologies, Lonza Inc.
About DCAT
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing. With over 400 corporate members, DCAT is headquartered in Robbinsville, New Jersey.
Contact:
Erin Sanders
DCAT Sr. Communications & Technology Specialist
609-208-1888